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Shear-wave elastography (SWE) is a recently developed ultrasound technique that can visualize 
and measure tissue elasticity. In breast ultrasonography, SWE has been shown to be useful for 
differentiating benign breast lesions from malignant breast lesions, and it has been suggested 
that SWE enhances the diagnostic performance of ultrasonography, potentially improving the 
specificity of conventional ultrasonography using the Breast Imaging Reporting and Data System 
criteria. More recently, not only has SWE been proven useful for the diagnosis of breast cancer, 
but has also been shown to provide valuable information that can be used as a preoperative 
predictor of the prognosis or response to chemotherapy.
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Introduction
Elastography is an imaging modality based on tissue stiffness or hardness, which is analogous to 
clinical palpation with ultrasonography for a malignancy [1,2]. Unlike a physical examination, which 
allows only the subjective judgment of the stiffness of a lesion, elastography has the potential to 
quantify stiffness [2]. In breast ultrasonography, two elastographic techniques are popular and differ 
in the type of stress applied: strain and shear-wave elastography (SWE) [3]. Strain elastography 
produces an image based on the relative displacement of the tissue from an external (manual 
compression of the transducer) or patient source. It is difficult to measure the amount of the force or 
stress during compression, and the absolute elasticity cannot be calculated [2,3]. Meanwhile, SWE 
using the acoustic radiation force induced by the ultrasound push pulse generated by the transducer 
provides quantitative elasticity parameters, as well as displaying a visual color overlay of elastic 
information in real time [2,3]. In this article, the clinical applications and the current role of SWE in 
breast ultrasonography are reviewed.
Image and Data Acquisition
With shear waves that are induced by the acoustic radiation force and propagate transversely in the 
tissue, SWE can provide a semitransparent color-coded image displaying the shear wave velocity 
(m/sec) or elasticity (kPa) for each pixel in real time, because the speed of the shear waves can be 
measured and is linked to the Young modulus (kPa) [3-6]. To obtain SWE images of breast lesions, 
the rectangular field-of-view box of the system is set to include the lesion itself as well as the 
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surrounding normal tissue; in this display, the tissue stiffness of 
each pixel in the image is shown as a semitransparent color map 
overlaid on the gray-scale image. The size of the rectangular region 
of interest (ROI) should be large enough to reveal any perilesional 
increased stiffness, because the maximum areas of stiffness in 
malignant lesions are almost always found in the area immediately 
adjacent to the lesions rather than in the lesion itself, and large 
enough to include normal fat tissue for the measurement of the 
lesion-to-fat ratio of elasticity (Fig. 1) [7,8]. In general, the range 
of the color scale within the ROI for breast lesions is from 0 (dark 
B
Fig. 1. A 38-year-old woman with a pathologically proven invasive ductal carcinoma. 
A. Shear-wave elastography (right) and B-mode images (left) on split-screen mode show a 13-mm, irregular mass with red, heterogeneous 
elasticity. B. The mean, minimum, maximum, and standard deviation of elasticity values were measured in kPa by placing the region of 
interest (ROI) over the stiffest part of the lesion (circle). The elasticity ratio of the mass to the reference fat tissue was measured by placing 
a second ROI over the surrounding fat tissue (dotted circle). C. The ROI for measuring the elasticity value was placed to include the whole 
breast lesion and the stiffest part of the lesion. 
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blue, indicating the lowest stiffness) to 180 kPa (red, indicating the 
highest stiffness), but the color scale can be adjusted to enhance 
the contrast of elasticity on the color map without any change in the 
absolute elasticity values [7]. 
To obtain high-quality SWE images, obtaining a good gray-scale 
image is essential before switching to the SWE mode because 
elastography images are often generated based on raw data from 
gray-scale images [9]. Since vibration energy is directly emitted 
from the probe, it is important to keep the angle of the probe 
perpendicular to the skin and the probe lightly touching the skin 
without consciously applying any vibration or compression [9,10]. 
If excessive compression or movement of the probe is applied, 
artifactual stiffness other than the target lesion is displayed as 
yellow to red, generally radiating from the skin surface or chest wall; 
this could be misinterpreted as high elasticity, even in a soft lesion. 
Using generous amounts of contact jelly and having the patient hold 
her breath may be effective in some cases to reduce artifacts [5,10]. 
Since it usually takes a few to several seconds for the color map of 
SWE to stabilize, depending on the case and the operator’s skill, the 
probe should be held still until the color display is completely stable 
before recording SWE images and measuring the elasticity of lesions 
in order to ensure that reliable results are obtained [9,10]. 
To measure the elasticity quantitatively in SWE for breast lesions, 
the most common practice is to place a 2- to 3-mm circular ROI over 
the stiffest part of the lesion, including the immediately adjacent stiff 
tissue or halo (Fig. 1). The elasticity parameters, including the mean 
(Emean), maximum (Emax), minimum (Emin), and standard deviation (ESD) 
of elasticity, are calculated automatically from the elasticity value 
of each pixel included in the ROI and displayed on the monitor of 
the ultrasound device in kPa or m/sec (Fig. 1). However, the size 
or shape of the ROI can be adjusted by the operator. In a previous 
study, the diagnostic performance of SWE, including its sensitivity, 
specificity, and accuracy, was influenced by the size of the ROI and 
varied across the elasticity parameters; therefore, the evaluation 
of all parameters with a 2-mm ROI was recommended [11]. In 
addition, a larger circular ROI encompassing the entire lesion as well 
as the stiffest part of the lesion can be used to quantify the elastic 
heterogeneity of a breast lesion by measuring ESD during SWE with 
good diagnostic performance (Fig. 1C) [12]. However, it is difficult to 
completely enclose irregular lesions with a circular ROI. To overcome 
this limitation, freehand ROI drawing techniques have been 
developed recently and are now commercially available (Fig. 2). The 
elasticity ratio (Eratio) of the breast lesion to the reference fat tissue 
can be measured by placing the first ROI over the stiffest part of the 
lesion, including the immediately adjacent stiff tissue or halo, and 
a second ROI in the fatty tissue of the breast (Fig. 1) [8]. Although 
the ROI for the reference fat can be set in various locations, since 
the diagnostic performance of Eratio was found not to be influenced 
by the measurement site of fat elasticity, images with a good quality 
should be obtained and the ROIs for the lesion and the surrounding 
fat should be set in areas without artifacts to avoid false-positive 
or -negative results [8]. Regarding the image acquisition planes, 
two orthogonal SWE images are recommended rather than a single 
SWE image, because breast tumors with intratumoral heterogeneity 
can appear to have different elasticity according to the selected 
imaging plane, just as they can show different morphology in gray-
scale images [13]. It is recommended to select the higher elasticity 
score when two SWE images have a similar image quality but show 
a discordant finding, and to select the elasticity score of the SWE 
with the higher image quality when the image quality of the other 
SWE image is poor. To obtain much more elasticity information 
about a breast lesion in further planes, including the stiffest plane, 
3-dimensional (3D) SWE can be used, which provides 3D volumetric 
color-coded elasticity maps of tissue stiffness in a single acquisition 
(Fig. 3) [14]. Unlike 2-dimensional SWE, in which the representative 
plane of the breast mass is chosen at the discretion of the operator 
Fig. 2. A 42-year-old woman with a pathologically proven invasive ductal carcinoma. A freehand region of interest was drawn manually 
by tracing the border of the mass using shear-wave elastography to measure lesion elasticity.
Breast shear-wave elastography
e-ultrasonography.org Ultrasonography 36(4), October 2017 303
and the stiffest portion of the tumor may be missed, 3D SWE can 
show the stiffest portion of the mass more easily and accurately [15].
Image and Data Interpretation
Quantitative Method 
The breast tissue elasticity measured by SWE varies depending 
on the inherent tissue characteristics of the breast structures. For 
example, Emean measured in vivo by SWE ranges from 5 to 10 kPa 
in fatty tissue and from 30 to 50 kPa in breast parenchyma [16]. 
Pathologic conditions change breast tissue elasticity; in general, 
benign lesions tend to be harder than normal breast tissue but 
softer than malignant lesions [4]. In clinical practice, Emean, Emax, ESD, 
and Eratio are popular quantitative SWE parameters in the differential 
diagnosis of breast lesions visible on ultrasonography. However, no 
clear consensus exists regarding the best quantitative parameter 
or the most appropriate cutoff values. The ranges of cutoff values 
between benign and malignant breast lesions for each parameter 
with 2-mm ROIs have been reported to be as follows: 33.3-80 
kPa (median, 59.35 kPa) for Emean; 46.7-93.8 kPa (median, 79.25 
kPa) for Emax; 6.3-13.9 kPa (median, 9.8 kPa) for ESD; and 3.18-
5.14 kPa (median, 3.56 kPa) for Eratio [3,7,8,12,14,15,17-27]. 
In the literature, Emean appears to be widely used in the diagnosis 
of breast lesions. However, ROI size should be considered when 
interpreting the results of Emean. Because Emean is the sum of all 
elasticity values of each pixel within the ROI divided by the number 
of pixels, its absolute value depends on the size of the ROI; that 
is, a higher Emean value for a smaller ROI is expected [28]. ESD, 
Fig. 3. A 58-year-old woman with a pathologically proven invasive ductal carcinoma. 
Multiplanar (A) and multislice (B-D; B, axial; C, sagittal; and D, coronal) images in three-dimensional shear-wave elastography show red, 
heterogeneous elasticity of the mass. 
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representing the average difference in elasticity value within the 
ROI to Emean, is also influenced by the ROI size [28]. As the size of 
the ROI changes, the sampling of the elasticity information becomes 
more variable, meaning that elastic heterogeneity will increase or 
decrease, particularly in a heterogeneous malignant lesion. For Emax, 
however, the stiffest part of the mass is always included within 
the ROI, regardless of the size of the ROI, and its absolute value is 
independent of the ROI size. For Eratio, the optimal measurement of 
reference fat elasticity is crucial, as fat elasticity is the denominator 
in calculating Eratio, and even a small difference in fat elasticity can 
cause a large difference in Eratio [8]. In addition, SWE anisotropy-the 
difference in lesion elasticity measured in two orthogonal planes-
could be used in the diagnosis of breast lesions [28]. Malignant 
lesions are more anisotropic than benign lesions.
Qualitative Method
From a color-coded elasticity map displayed in real time on SWE, the 
elasticity of breast lesions can be qualitatively evaluated for their 
diagnosis. In general, color map features can be visually assessed 
on the spot before measuring elasticity quantitatively, making the 
qualitative method more instantaneous. The color displayed for 
each pixel represents the elasticity information of the corresponding 
tissue, and once the color map features of the lesion are screened, 
an ROI can be placed over the stiffest part of the lesion to measure 
the elasticity quantitatively. For the qualitative assessment of breast 
lesions on SWE, a 4-color pattern classification based on color 
stiffness and heterogeneity was proposed by Tozaki and Fukuma 
[29]: in pattern 1, no difference from the color around the lesion is 
observed at the margin of the lesion or in its interior (coded blue 
homogeneously); in pattern 2, a color that differs from the color 
around the lesion is observed at the margin or in the interior of the 
lesion, but it extends beyond the lesion and continues vertically in 
cords on the cutaneous side or the thoracic wall side (vertical stripe 
pattern artifacts); in pattern 3, a localized colored area is present 
at the margin of the lesion; and in pattern 4, colored areas are 
present in the interior of the lesion heterogeneously (Fig. 4) [29,30]. 
Pattern 2 is a unique artifact frequently observed during SWE 
examinations, with reported ranges from 7% to 24% [24,29-31]. 
Patterns 3 and 4 are characterized by peripheral increased stiffness 
(the “stiff rim sign”) and heterogeneous color map features, 
suggestive of malignancy [7]. The stiff rim sign may be caused by 
(1) a desmoplastic reaction or the infiltration of cancer cells into 
the interstitial tissues or the intraductal component; or (2) internal 
low shear wave amplitude and/or noise as well as peripheral high-
speed shear wave in the lesion caused by attenuation of the energy 
of the shear wave in the periphery of the lesion [7,32]. Elastic 
heterogeneity is regarded to represent histologic heterogeneity of 
malignant lesions that are in part more cellular due to lymphocytic 
infiltration and/or in part more necrotic [12]. Berg et al. [19] 
proposed qualitative E values, Ecol (a 6-point color score of maximum 
elasticity: red, orange, green, light blue, dark blue, or black), 
Ehomo (homogeneity of elasticity: very homogeneous, reasonably 
homogeneous, or heterogeneous), and Esha (lesion shape: oval, 
round, or irregular). 
In the fifth edition of the Breast Imaging Reporting and Data 
System (BI-RADS), descriptors for qualitative elasticity assessment 
were added: soft, intermediate, and hard. It is emphasized that a 
soft elastogram must not supersede morphologic analysis. Stiffness 
as a feature of malignant masses may be considered along with 
their much more important morphologic characteristics [33].
Clinical Applications of SWE
Differentiation of Benign and Malignant Breast Lesions 
The diagnostic performance of SWE is good for differentiating 
between benign and malignant breast lesions. In literature, the 
median sensitivity, specificity, and area under receiver operating 
curve of each quantitative parameter have been reported as follows: 
88.6% (range, 81.0% to 95.8%), 89.9% (range, 68.2% to 93.8%), 
and 0.932 (range, 0.788 to 0.974) for Emean; 90.3% (range, 60.9% 
to 97.0%), 81.8% (range, 77% to 100%), and 0.931 (range, 0.741 
to 0.961) for Emax; 89.2% (range, 83.1% to 91.1%), 91.1% (range, 
67.9% to 93.0%), and 0.899 (range, 0.761 to 0.964) for ESD; and 
88.0% (range, 71.4% to 96.7%), 93.7% (range, 90.6% to 100%), 
and 0.952 (range, 0.917 to 0.987) for Eratio, respectively [3,6,7,12-
15,17,21-26,32,34-39]. The best-performing SWE parameter 
in diagnosing breast lesions has been reported to be Emax or Eratio 
[15,19,25,26,38,40].
The combination of SWE with conventional B-mode ultrasound 
increases the diagnostic performance for breast lesions, compared 
with conventional B-mode ultrasound alone [3,4,7,18,19,25,26,34]. 
In a meta-analysis, the sensitivity, specificity, and the area under 
receiver operating curve were reported as follows: 97.1% (95% 
confidence interval [CI], 94.1% to 98.6%), 80.1% (95% CI, 73.3% 
to 85.6%), and 0.96 (95% CI, 0.94 to 0.97) for both techniques in 
combination; and 94.9% (95% CI, 88.1% to 97.9%) and 55.2% 
(95% CI, 26.4% to 80.9%), and 0.93 (95% CI, 0.90 to 0.95) for 
conventional B-mode ultrasound alone, respectively [41]. The use 
of SWE as an adjunct to conventional B-mode ultrasound can 
increase diagnostic confidence and improve patient management. 
More specifically, SWE features can help reclassify BI-RADS category 
3 or 4a lesions by morphologic criteria on conventional B-mode 
ultrasound. In the BE1 multinational prospective study, the use of 
SWE features to downgrade BI-RADS category 4a lesions to follow-
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radiologists have greater confidence when its findings concur with 
conventional ultrasound findings [43].
Prediction of Breast Cancer Prognosis
Breast cancer is considered to be a group of heterogeneous 
diseases, in terms of morphology, clinical course, and response 
to treatment [44]. To characterize breast cancer and predict its 
prognosis accurately is the mainstay of successful treatment. 
Clinicopathological features such as histological type, tumor size, 
histological grade, the presence of lymph node metastasis, and 
lymphovascular invasion have been well established as prognostic 
factors of breast cancer. Through gene expression profiling, breast 
up or to upgrade BI-RADS category 3 lesions to biopsy improved 
specificity from 61.1% for B-mode ultrasound alone to 78.5% 
by applying visual color stiffness or 77.4% by using Emax, without 
changing the sensitivity [19]. This result is underscored by other 
studies suggesting that the addition of SWE reduced the number of 
unnecessary biopsies by enabling a switch to follow-up in benign BI-
RADS category 4a lesions [3,13,25,30]. In addition, using the same 
criteria of the likelihood of malignancy as the BE1 study group, SWE 
helped downgrade benign BI-RADS category 3 lesions to category 2 
and reduce the number of unnecessary initial short-term follow-up 
visits, especially when Emax was ≤20 kPa or the visual color stiffness 
was black to dark blue [42]. In clinical practice, SWE frequently helps 
Fig. 4. Four color patterns on shear-wave elastography. 
A. Pattern 1: no difference from the color around the lesion is observed at the margin of the lesion or in its interior. B. Pattern 2: a color 
that differs from the color around the lesion is observed at the margin or in the interior of the lesion, but it extends beyond the lesion and 
continues vertically in cords on the cutaneous side or the thoracic wall side. C. Pattern 3: a localized colored area is present at the margin of 
the lesion. D. Pattern 4: colored areas are present in the interior of the lesion heterogeneously. 
C D
A B
Ji Hyun Youk, et al.
306  Ultrasonography 36(4), October 2017 e-ultrasonography.org
cancer has been divided into four subtypes: luminal A, luminal B, 
human epidermal growth factor receptor 2 (HER2)-enriched, and 
basal cell-like subtypes, showing different clinical outcomes [44]. 
As a surrogate for molecular classification, immunohistochemical 
profiling for the expression of the hormonal receptors HER2 and 
Ki-67 has been suggested, and has been shown to be associated 
with different clinicopathological features, prognosis, and treatment 
responses [44]. Regarding SWE, a large invasive size, high nuclear 
grade, high histologic grade, and lymphovascular invasion were 
reported to be associated with increased stiffness of invasive breast 
cancer [44-47]. Estrogen receptor negativity, progesterone receptor 
negativity, p53 positivity, and Ki-67 positivity were significantly 
associated with a higher Eratio, and triple-negative and HER2-positive 
tumors showed greater stiffness than estrogen receptor-positive 
tumors [46,47]. Interestingly, some aggressive tumors, such as high-
grade cancers and triple-negative tumors, are likely to be assessed 
as BI-RADS category 3 in B-mode ultrasound, but SWE may 
provide additional information for diagnosing those benign-looking 
malignancies [47]. 
Predicting the axillary lymph node status in patients with newly 
diagnosed breast cancer is an integral component of breast cancer 
management, including the staging, treatment plan, and prognosis 
[48]. Ultrasonography has been performed for the noninvasive 
preoperative evaluation of the axillary nodal basin because it is 
widely available and easily incorporated into the standard workup 
for breast cancer patients [49]. Ultrasonographic criteria based on 
size or morphologic characteristics have shown variable diagnostic 
performance for metastatic lymph nodes [50]. In two previous 
studies-one in vivo and the other ex vivo-of SWE for sentinel 
axillary lymph nodes in patients with breast cancer [51,52], 
greater axillary lymph node stiffness was correlated with the risk 
of metastasis, and the high specificity of lymph node cortical 
stiffness can be complementary to B-mode ultrasound for decision-
making regarding fine-needle aspiration biopsy. In future, further 
investigations of larger populations are needed to validate these 
results and apply SWE in clinical practice.
Prediction of the Response of Breast Cancers to Neo-
adjuvant Chemotherapy 
Neoadjuvant chemotherapy (NAC) has been applied as an 
established treatment strategy for tumor down-staging in 
patients with breast cancer who would not be optimally treated 
by immediate surgery [53]. A complete pathologic response after 
NAC may be a predictor of a low risk of subsequent recurrence 
and longer disease-free survival [54,55]. However, the response 
to NAC can be quite variable. The early and accurate prediction of 
responsive and resistant tumors to NAC is crucial to avoid futile 
chemotherapy and to guide more effective treatment strategies, such 
as modifying the chemotherapy regimen or optimizing the timing 
of surgery in nonresponsive patients [53,55]. A clinical examination 
combined with conventional imaging modalities has not yet become 
sensitive or specific enough to predict pathologic responses to 
NAC. Interestingly, recent studies have reported that increased 
stromal gene expression may be a predictor of response to NAC 
and that tumors with disorganized stroma had a reduced pathologic 
response to NAC, which means that stromal factors as well as tumor 
factors are important in predicting the response to NAC [53,56,57]. 
Considering that tumor stiffness is related to the collagen content 
in the stroma, stromal stiffness measured by SWE may be useful as 
an imaging biomarker for stromal structural abnormalities and the 
response to NAC [20,53]. Tumor elasticity measured by SWE before 
NAC had a significant relationship with a subsequent reduction in 
the cellularity of the primary tumor in response to NAC [20]. During 
NAC, the relative changes in tumor elasticity showed a significant 
correlation with the response to NAC, and the second NAC cycle 
was recommended as the optimal time point for performing SWE 
evaluations to reduce the chance of unnecessary cytotoxic exposure 
or to perform surgery in patients with NAC resistance [53-55,58]. A 
previous study suggested the optimal relative change in the stiffness 
threshold to be -36.1%, with a sensitivity of 73% and a specificity 
of 86%, to distinguish between responders and nonresponders after 
two cycles of NAC [55].
Pitfalls
Although quantitative elasticity information obtained by SWE 
in addition to B-mode ultrasound has improved diagnostic 
performance, false results have been reported in 6.4%-36.6% 
of cases, in which the imaging results did not correspond to the 
pathologic results [59]. Specifically, the false-positive rates of benign 
masses (53% using qualitative analysis and 22%-37% using 
quantitative analysis) were reported to be higher than the false-
negative rates of malignant masses (8% using qualitative analysis 
and 6%-10% using quantitative analysis) [23,27]. Considering 
that benign breast lesions showing false-positive SWE findings 
were significantly larger, the false-positive results can be explained 
by the size of the breast mass, as larger masses are likely to cause 
the probe to be unevenly applied to the skin above the masses, 
which could hinder adequate image acquisition [23]. Other lesion-
related factors contributing to false diagnoses in SWE may include 
the presence of pure in situ disease, smaller malignant masses, 
malignant masses with a circumscribed margin and an abrupt lesion 
boundary, and the grade of invasive disease [23,27,60]. Aside from 
the intrinsic tumor characteristics, patient-related or clinical factors 
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associated with false elastography features include the mode 
of detection (symptomatic vs. mammography screening), age at 
diagnosis, breast thickness, lesion depth, distance from the nipple 
to the lesion, and the quality of the image [23,27,59,60]. When 
SWE examinations are performed and interpreted for breast masses, 
investigators should take into consideration the clinical and lesion-
related factors that are associated with inaccurate elastography 
findings.
Summary
Breast elastography is now an adjunct tool in breast ultrasono-
graphy. It is easily performed in clinical practice, adding only a 
short amount of time to breast ultrasonography. To ensure the best 
possible performance of SWE in the diagnosis of breast cancer, the 
technique should be optimized to acquire high-quality images, and 
practitioners should properly interpret the acquired images and 
data. One of the best applications of SWE is the characterization of 
breast masses categorized as BI-RADS category 3 and 4a, in order to 
attempt to reduce unnecessary breast biopsies. In addition, SWE can 
provide additional information on predicting breast cancer prognosis 
and response to NAC. However, the possibility of false-positive and 
false-negative results should be considered during interpretation. 
An adequate understanding of the features of each elastography 
method allows proper imaging and diagnosis to be carried out, 
confirming that elastography is indeed a clinically useful tool.
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